Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 29;12:10415–10425. doi: 10.2147/OTT.S228631

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Chai et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

rVL2 inhibits cell proliferation and glycolysis of cervical cancer cells in vivo. (A) Treatment with rVL2 slowed the speed of tumor growth in vivo (P < 0.05). (B and C) The tumor volume and weight in the experimental group were significantly lower than those in control group (**P < 0.01). (D) rVL2 can significantly suppress the glucose uptake in cervical cancer in vivo and resulted in a lower SUVmax value (**P < 0.01). (E) Immunohistochemical analyses of ITGB7, p-FAK, p-AKT1, and p- C/EBPβ expression in tissues. (F) The expression levels of GLUT1, LDHA, HK2, G6P, PKM2, PGK1 ALDOA, FBP1, and PFKP were detected by real-time PCR in xenograft tumors and the corresponding controls (*P < 0.05, **P< 0.01).